-transparent.png){kind=logo}
OBJECTIVE To see whether parathyroid hormone related protein has a humoral role in breast cancer. METHODS Plasma concentrations and tumour expression of parathyroid hormone related protein were determined (by two site immunoradiometric assay and immunohistochemistry respectively) in women with breast cancer and related to the presence of bone metastases and serum calcium concentrations. METHODS Plasma concentrations of parathyroid hormone related protein were measured in 57 women with early breast cancer without apparent bone metastases, 28 women with bone metastases, and 13 women with bone metastases and hypercalcaemia. Tissue positivity for parathyroid hormone related protein was determined retrospectively in 106 primary breast tumours from women without apparent bone metastases and 72 tumours from women with bone metastases, 25 of whom subsequently developed hypercalcaemia. RESULTS Plasma parathyroid hormone related protein concentrations were detectable (greater than 0.23 pmol/l) in 12 (92%) of the 13 hypercalcaemic patients with bone metastases compared with 10 (36%) of the 28 normocalcaemic patients with bone metastases and five (9%) of the 57 normocalcaemic patients without bone metastases. Parathyroid hormone related protein concentrations were significantly higher in hypercalcaemic than normocalcaemic patients with bone metastases. Tumour staining was positive for parathyroid hormone related protein in 22 (88%) of the 25 primary breast cancers from patients with bone metastases. Tumour staining was positive for parathyroid hormone related protein in 22 (88%) of the 25 primary breast cancers from patients with bone metastases who later developed hypercalcaemia compared with 25 (53%) of the 47 from women in this group who remained normocalcaemic and 55 (52%) of the 106 early breast cancers from women without known metastases. CONCLUSIONS Tumour derived parathyroid hormone related protein may have an important humoral role in hypercalcaemia associated with metastatic breast cancer.
N J Bundred, and
W A Ratcliffe, and
R A Walker, and
S Coley, and
J M Morrison, and
J G Ratcliffe
January 2001,
Clinical oncology (Royal College of Radiologists (Great Britain)),
N J Bundred, and
W A Ratcliffe, and
R A Walker, and
S Coley, and
J M Morrison, and
J G Ratcliffe
February 1998,
European journal of cancer (Oxford, England : 1990),
N J Bundred, and
W A Ratcliffe, and
R A Walker, and
S Coley, and
J M Morrison, and
J G Ratcliffe
March 1995,
British journal of haematology,
N J Bundred, and
W A Ratcliffe, and
R A Walker, and
S Coley, and
J M Morrison, and
J G Ratcliffe
June 1994,
The Journal of pathology,
N J Bundred, and
W A Ratcliffe, and
R A Walker, and
S Coley, and
J M Morrison, and
J G Ratcliffe
November 1989,
Clinical endocrinology,
N J Bundred, and
W A Ratcliffe, and
R A Walker, and
S Coley, and
J M Morrison, and
J G Ratcliffe
March 2003,
International journal of clinical practice,
N J Bundred, and
W A Ratcliffe, and
R A Walker, and
S Coley, and
J M Morrison, and
J G Ratcliffe
June 1992,
Journal of clinical pathology,
N J Bundred, and
W A Ratcliffe, and
R A Walker, and
S Coley, and
J M Morrison, and
J G Ratcliffe
March 2006,
Journal of the European Academy of Dermatology and Venereology : JEADV,
N J Bundred, and
W A Ratcliffe, and
R A Walker, and
S Coley, and
J M Morrison, and
J G Ratcliffe
January 1990,
Lancet (London, England),
N J Bundred, and
W A Ratcliffe, and
R A Walker, and
S Coley, and
J M Morrison, and
J G Ratcliffe
January 1991,
Lancet (London, England),
